JP2024529033A5 - - Google Patents

Info

Publication number
JP2024529033A5
JP2024529033A5 JP2024506984A JP2024506984A JP2024529033A5 JP 2024529033 A5 JP2024529033 A5 JP 2024529033A5 JP 2024506984 A JP2024506984 A JP 2024506984A JP 2024506984 A JP2024506984 A JP 2024506984A JP 2024529033 A5 JP2024529033 A5 JP 2024529033A5
Authority
JP
Japan
Prior art keywords
sequence
seq
identity
nucleic acid
itr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529033A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/110545 external-priority patent/WO2023011632A1/zh
Publication of JP2024529033A publication Critical patent/JP2024529033A/ja
Publication of JP2024529033A5 publication Critical patent/JP2024529033A5/ja
Pending legal-status Critical Current

Links

JP2024506984A 2021-08-06 2022-08-05 Ｎｄ４変異により引き起こされるレーベル遺伝性視神経症を治療するための組成物及び方法 Pending JP2024529033A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110899561.X 2021-08-06
CN202110899561 2021-08-06
PCT/CN2022/110545 WO2023011632A1 (zh) 2021-08-06 2022-08-05 用于治疗由于nd4突变造成的莱伯氏遗传性视神经病变的组合物和方法

Publications (2)

Publication Number Publication Date
JP2024529033A JP2024529033A (ja) 2024-08-01
JP2024529033A5 true JP2024529033A5 (https=) 2025-06-12

Family

ID=85155306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506984A Pending JP2024529033A (ja) 2021-08-06 2022-08-05 Ｎｄ４変異により引き起こされるレーベル遺伝性視神経症を治療するための組成物及び方法

Country Status (11)

Country Link
US (1) US20240376164A1 (https=)
EP (1) EP4382601A4 (https=)
JP (1) JP2024529033A (https=)
KR (1) KR20240042489A (https=)
CN (1) CN116024266A (https=)
AR (1) AR126727A1 (https=)
AU (1) AU2022322957A1 (https=)
BR (1) BR112024002305A2 (https=)
CA (1) CA3228344A1 (https=)
MX (1) MX2024001597A (https=)
WO (1) WO2023011632A1 (https=)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4789734A (en) 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DK0678034T3 (da) 1993-01-11 1999-11-08 Dana Farber Cancer Inst Inc Induktion af cytotoksiske T-lymfocytreaktioner
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
CN1206361C (zh) * 1999-09-10 2005-06-15 本元正阳基因技术股份有限公司 系列通用型腺病毒伴随病毒载体的构建及用途
CN102634527B (zh) * 2012-04-11 2013-11-06 华中科技大学同济医学院附属同济医院 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法
CN111068071A (zh) * 2018-10-22 2020-04-28 武汉纽福斯生物科技有限公司 基因治疗Leber遗传学视神经病变
CN113528510A (zh) * 2018-06-29 2021-10-22 武汉纽福斯生物科技有限公司 治疗遗传性视神经病变的组合物和方法
SG11202101032VA (en) * 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Ltd Company Compositions and methods for treating leber's hereditary optic neuropathy
EP3908656A4 (en) * 2019-01-07 2022-10-05 California Institute of Technology GAS VESICLE EXPRESSION SYSTEMS, GAS VESICLE CONSTRUCTS AND ASSOCIATED GENETIC CIRCUITS, VECTORS, MAMMALIAN CELLS, HOSTS, COMPOSITIONS, METHODS AND SYSTEMS
CN113025633B (zh) * 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
WO2021138559A1 (en) * 2019-12-31 2021-07-08 Swanbio Therapeutics Limited Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn)

Similar Documents

Publication Publication Date Title
JP7607007B2 (ja) 変異ａａｖ、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
JP2021121638A5 (https=)
JP6373763B2 (ja) Ａａｖベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法
ES2640586T3 (es) Secuencias del factor VIII
ES2768763T3 (es) Vectores rAAV mejorados y métodos para la transducción de fotorreceptores y células EPR
JP2022530633A5 (https=)
JP2023505522A5 (https=)
JP2022521851A5 (https=)
JP2022531861A5 (https=)
JP2020510428A5 (https=)
JP2022523766A5 (https=)
JP2023551903A5 (https=)
JP2023504773A5 (https=)
JP2022512589A5 (https=)
JP2023534037A5 (https=)
JP2025513066A5 (https=)
JP2023503850A5 (https=)
JP2024517710A5 (https=)
CA3230004A1 (en) Aav particles comprising liver-tropic capsid protein and acid alpha-glucosidase and use to treat pompe disease
CN112029773B (zh) 编码bdnf的核酸及其应用
CN112143701A (zh) 基于rna定点编辑的抑制脉络膜新生血管形成的方法及试剂
CA3178591A1 (en) Immunosuppressive agents and viral delivery re-dosing methods for gene therapy
JP2024529033A5 (https=)
EP4368203A1 (en) Construction and use of anti-vegf antibody in-vivo expression system
JP2024542950A5 (https=)